- Home
- PTHL vs VRCA Comparison
PTHL vs VRCA Comparison
Compare PTHL & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- VRCA
- Stock Information
- Founded
- PTHL 1998
- VRCA 2013
- Country
- PTHL China
- VRCA United States
- Employees
- PTHL N/A
- VRCA N/A
- Industry
- PTHL
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- VRCA Health Care
- Exchange
- PTHL Nasdaq
- VRCA Nasdaq
- Market Cap
- PTHL 59.6M
- VRCA 58.0M
- IPO Year
- PTHL 2024
- VRCA 2018
- Fundamental
- Price
- PTHL $3.90
- VRCA $0.44
- Analyst Decision
- PTHL
- VRCA Hold
- Analyst Count
- PTHL 0
- VRCA 5
- Target Price
- PTHL N/A
- VRCA $6.00
- AVG Volume (30 Days)
- PTHL 93.1K
- VRCA 543.9K
- Earning Date
- PTHL 02-11-2025
- VRCA 05-12-2025
- Dividend Yield
- PTHL N/A
- VRCA N/A
- EPS Growth
- PTHL N/A
- VRCA N/A
- EPS
- PTHL N/A
- VRCA N/A
- Revenue
- PTHL $448,196.00
- VRCA $7,566,000.00
- Revenue This Year
- PTHL N/A
- VRCA $118.94
- Revenue Next Year
- PTHL N/A
- VRCA $94.35
- P/E Ratio
- PTHL N/A
- VRCA N/A
- Revenue Growth
- PTHL N/A
- VRCA 47.66
- 52 Week Low
- PTHL $1.32
- VRCA $0.39
- 52 Week High
- PTHL $6.45
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- VRCA 32.87
- Support Level
- PTHL N/A
- VRCA $0.39
- Resistance Level
- PTHL N/A
- VRCA $0.66
- Average True Range (ATR)
- PTHL 0.00
- VRCA 0.07
- MACD
- PTHL 0.00
- VRCA -0.01
- Stochastic Oscillator
- PTHL 0.00
- VRCA 17.82
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.